GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Valuation Rank

PHAXIAM Therapeutics (XPAR:PHXM) Valuation Rank


View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PHAXIAM Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Valuation Rank
Comparable Companies
XPAR:ALVIO XPAR:GNRO XPAR:ALGEN XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:ABNX XPAR:POXEL XPAR:FALG XPAR:ALHYG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PHXM:USA 2E41:Germany
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Website
https://www.erytech.com
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.